Table 3.
Clinical trials with monoclonal antibodies in Ewing sarcoma
| Status | Phase | Name of monoclonocal antibody | Target antigen | Trial number |
| C | III | Ganitumab+chemotherapy | IGF-R1 | NCT02306161 |
| C | II | Cixutumumab | IGF-R1 | NCT00668148 |
| C | I/II | Figitumumab | IGF-R1 | NCT00560235 |
| C | II | Robatumumab | IGF-R1 | NCT00617890 |
| C | II | R1507 | IGF-R1 | NCT00642941 |
| C | I | Dalotuzumab | IGF-R1 | NCT01431547 |
| C | I | BIIB022 | IGF-R1 | NCT00555724 |
| C | II | Bevacizumab+VCT | VEGF-R | NCT00516295 |
| T | I | Lexatumumab | TRAIL-R | NCT00428272 |
| C | I | Ontuxizumab | Endosialin | NCT01748721 |
| C | I | Enoblituzumab | B7-H3 | NCT02982941 |
| C | I | Hu14. 18K322A | GD2 | NCT00743496 |
C, completed; R, recruiting; T, terminated.